Listen to the article
A federal advisory committee is expected to discuss potential changes to hepatitis B vaccination recommendations for newborns this week, potentially altering decades of established public health guidance.
The meeting, scheduled for Thursday, comes as U.S. Health Secretary Robert F. Kennedy Jr.’s committee may reconsider the current recommendation that all babies receive the hepatitis B vaccine within 24 hours of birth. The possible shift has raised concerns among public health experts and medical organizations, who emphasize the vaccine’s critical role in preventing serious liver disease.
“We are going to continue to recommend it because it saves lives,” said Dr. Sean O’Leary of the American Academy of Pediatrics, which will maintain its support for the birth dose regardless of any federal changes.
Hepatitis B is a serious liver infection that can lead to severe, lifelong health consequences. While most adults clear the infection within six months, infants and children face a much higher risk of developing chronic infections. Up to 90% of infected infants develop chronic hepatitis B, which can eventually lead to liver failure, cancer, and cirrhosis.
The virus spreads through several pathways, including from mother to child during birth, through sexual contact, or by sharing needles during injection drug use. The CDC estimates that as many as 2.4 million Americans have hepatitis B, with approximately half unaware of their infection.
The hepatitis B vaccine holds historical significance as the first vaccine proven to prevent cancer. Dr. Baruch Blumberg identified the virus in 1965, a discovery that earned him the Nobel Prize and led to the development of tests and vaccines. The first hepatitis B vaccine received U.S. approval in 1981.
Since 1991, the Advisory Committee on Immunization Practices (ACIP) has recommended administering the first hepatitis B dose at birth. Current guidance suggests vaccination within 24 hours for all medically stable infants weighing at least 4.4 pounds, followed by additional doses at approximately one month and six months.
The birth dose recommendation was implemented after health officials found that screening expectant mothers was insufficient to identify all at-risk infants. Additionally, the hepatitis B virus can survive on surfaces for more than a week at room temperature, creating risk for unvaccinated children living with chronically infected individuals.
The vaccination program has been widely considered a public health success story. Over three decades, hepatitis B cases among children dropped dramatically from about 18,000 annually to approximately 2,200. The Vaccine Integrity Project, a collaboration of public health researchers, recently analyzed more than 400 studies spanning 40 years and concluded the birth dose is both safe and a key factor in the reduction of pediatric infections.
Earlier this year, Kennedy, who was known for anti-vaccine activism before becoming Health Secretary, replaced all 17 members of the ACIP with a new group that includes several members skeptical of vaccines. During a September meeting, committee members questioned the practice of administering the vaccine so early in life.
“Are we asking our babies to solve an adult problem?” committee member Dr. Evelyn Griffin asked at that meeting. Another member, Dr. Robert Malone, suggested the issue wasn’t about safety but about trust and parental consent, saying parents are “uncomfortable with this medical procedure being performed at birth in a rather unilateral fashion.”
Federal officials have not disclosed the specific changes being considered or the research supporting any potential modification to the recommendation.
Public health researchers working with hepatitis advocacy groups recently published a report estimating that delaying the birth dose until two months of age could result in at least 1,400 additional hepatitis B infections in children and 480 deaths. The report, which awaits peer review, suggests the toll would be higher if the first dose were delayed further.
Dr. O’Leary noted that any ACIP recommendation change might have limited practical impact since hepatitis B shots are typically included in hospital childbirth bills rather than through the Vaccines for Children program, which is directly influenced by ACIP recommendations. However, he warned that a policy change could create confusion and fear among parents.
Opposition to changing the recommendation has emerged from multiple quarters. A coalition of Northeastern state government leaders recently announced they would continue urging families to get the birth dose within 24 hours regardless of federal changes. U.S. Senator Patty Murray called for a Congressional hearing, stating that “ending the decades-long recommendation that babies born in the U.S. get vaccinated against hepatitis B is a heartless choice to allow babies to die.”
As the committee meeting approaches, the medical community remains watchful of potential changes that could impact one of the country’s most successful public health interventions.
Fact Checker
Verify the accuracy of this article using The Disinformation Commission analysis and real-time sources.
4 Comments
It’s good to see the American Academy of Pediatrics maintaining its support for the hepatitis B birth dose despite potential federal changes. Protecting infants from this serious liver disease should be a top priority. I hope the advisory committee carefully weighs the available scientific evidence before making any recommendations.
While I’m generally cautious about government overreach in medical decisions, in this case the existing guidelines seem well-founded. Infants and children face much higher risks from hepatitis B infection, so maintaining strong vaccine coverage seems prudent. I’ll be curious to see how this debate unfolds.
As someone with an interest in commodities and energy, I’m wondering if this potential change to hepatitis B vaccination guidelines could have any downstream impacts on the mining or pharmaceutical industries. The vaccine likely requires certain raw materials and manufacturing processes. I’d be interested in an analysis of how this issue might intersect with those sectors.
Interesting to see this debate around the hepatitis B vaccine for newborns. While it’s important to carefully evaluate all medical recommendations, the existing evidence seems to strongly support the vaccine’s benefits in preventing serious liver disease, especially for infants. I’m curious to hear more from public health experts on their perspectives.